Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ehave Inc EHVVF

Ehave, Inc. is a Canada-based company, which is an engaged in the digital therapeutics delivering evidence-based therapeutic interventions to patients. The Company’s primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to... see more

Recent & Breaking News (GREY:EHVVF)

Ehave Provides Progress Update on its HPPD Study with University of Melbourne

GlobeNewswire February 2, 2023

FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder

GlobeNewswire December 15, 2022

Ehave Shareholder from CEO Ben Kaplan and Corporate Update

GlobeNewswire December 7, 2022

Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022

GlobeNewswire June 3, 2022

Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

GlobeNewswire June 1, 2022

Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ

GlobeNewswire May 23, 2022

Ehave Announces MetaHealthU Will Enter The Market With A Focus On HPPD

GlobeNewswire April 19, 2022

Mycotopia Therapies Inc. To Enter $13 Billion Medicinal Mushroom Market With HAVN Life Sciences' Biopharmaceuticals And Ei.Ventures MANA Products

GlobeNewswire March 21, 2022

Ehave Continues Expansion Of KetaDASH Mobile Psychedelic Service By Providing Licensed Psychotherapists And Registered Nurses

GlobeNewswire March 3, 2022

Ehave, Inc. Licensing Partner Vastmindz Seen By Millions Of Viewers On Unicorn Hunter

GlobeNewswire February 24, 2022

Ehave, Inc. Launches KetaDASH, Its In-Home Ketamine Therapy In The San Francisco And Sacramento Market

GlobeNewswire February 15, 2022

Ehave, Inc. Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California Based Rejuv IV

GlobeNewswire February 9, 2022

Ehave Issues Shareholder Letter and Provides Corporate Update

GlobeNewswire January 31, 2022

Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures

GlobeNewswire December 8, 2021

Ehave, Inc. To Sponsor Major Psychedelics Conference, Wonderland: Miami

Newsfile November 5, 2021

2021 Psychedelic Investor Guide Released

GlobeNewswire October 20, 2021

Ehave Hires Contract Research Organization To Conduct Ketamine Clinical Trial In Miami, Florida

GlobeNewswire October 12, 2021

Psychedelic Stock Review Initiates Coverage on Ehave Inc.

GlobeNewswire September 30, 2021

Ehave Announces Inclusion in the 2021 Psychedelic Investor Guide

GlobeNewswire September 27, 2021

Ehave Appoints Board-Certified Gastroenterologist And Licensed Physician Dr. Rahul Dixit To Its Medical Advisory Board

GlobeNewswire September 21, 2021